CIK 0002044725 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Evommune, Inc.
Sign in to watch- Ticker
- EVMN
- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 850742575
- Phone
- (650) 223-7745
- Business address
- 1891 PAGE MILL RD, PALO ALTO, CA
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-11-07 | Moss Gregory S. Chief Business & Legal Officer | Conversion | +3,175 | 3,175 | ||
| 2025-11-07 | Moss Gregory S. Chief Business & Legal Officer | Conversion · Series B Preferred Stock | −25,000 | 0 | ||
| 2025-11-07 | Bauer Eugene Chief Medical Officer | Conversion | +25,812 | 272,296 | ||
| 2025-11-07 | Bauer Eugene Chief Medical Officer | Conversion · Series Seed Preferred Stock | −206,355 | 0 | ||
| 2025-11-07 | Bauer Eugene Chief Medical Officer | Conversion · Series B Preferred Stock | −12,500 | 0 | ||
| 2025-11-07 | Pena Luis C. President & CEO | Conversion | +24,225 | 682,821 | ||
| 2025-11-07 | Pena Luis C. President & CEO | Conversion · Series Seed Preferred Stock | −206,355 | 0 | ||
| 2025-11-07 | Hopfner Robert Lorne Director | Conversion | +3,026 | 3,026 | ||
| 2025-11-07 | Hopfner Robert Lorne Director | Conversion | +1,441,032 | 1,441,032 | ||
| 2025-11-07 | Hopfner Robert Lorne Director | Conversion | +1,632,441 | 1,632,441 | ||
| 2025-11-07 | Hopfner Robert Lorne Director | Conversion | +294,502 | 294,502 | ||
| 2025-11-07 | Hopfner Robert Lorne Director | Conversion · Series Seed Preferred Stock | −25,790 | 0 | ||
| 2025-11-07 | Hopfner Robert Lorne Director | Conversion · Series Seed Preferred Stock | −7,145,647 | 0 | ||
| 2025-11-07 | Hopfner Robert Lorne Director | Conversion · Series Seed Preferred Stock | −3,572,816 | 0 | ||
| 2025-11-07 | Hopfner Robert Lorne Director | Conversion · Series A Preferred Stock | −2,582,243 | 0 | ||
| 2025-11-07 | Hopfner Robert Lorne Director | Conversion · Series A Preferred Stock | −7,230,283 | 0 | ||
| 2025-11-07 | Hopfner Robert Lorne Director | Conversion · Series B Preferred Stock | −1,895,260 | 0 | ||
| 2025-11-07 | Hopfner Robert Lorne Director | Conversion · Series B Preferred Stock | −2,104,740 | 0 | ||
| 2025-11-07 | Hopfner Robert Lorne Director | Conversion · Series C Preferred Stock | −313,571 | 0 | ||
| 2025-11-07 | Hopfner Robert Lorne Director | Conversion · Series C Preferred Stock | −313,571 | 0 |
Page 4 of 6 · 109 trades